CoChat
Sign Up
Cited by 1,268Adrenal Hormones and DisordersPharmacovigilance and Adverse Drug ReactionsRheumatoid Arthritis Research and Therapies

A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

Open access
Liu, Dora, Ahmet, Alexandra, Ward, Leanne, Krishnamoorthy, Preetha, Mandelcorn, Efrem D, Leigh, Richard, Brown, Jacques P, Cohen, Albert +1 more·2013·Allergy, Asthma & Clinical Immunology
DOI 10.1186/1710-1492-9-30PMC PMC3765115
Open this paper in CoChat — free accountOpen PDF

Abstract

Systemic corticosteroids play an integral role in the management of many inflammatory and immunologic conditions, but these agents are also associated with serious risks. Osteoporosis, adrenal suppression, hyperglycemia, dyslipidemia, cardiovascular disease, Cushing’s syndrome, psychiatric disturbances and immunosuppression are among the more serious side effects noted with systemic corticosteroid therapy, particularly when used at high doses for prolonged periods. This comprehensive article reviews these adverse events and provides practical recommendations for their prevention and management based on both current literature and the clinical experience of the authors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1710-1492-9-30

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In real-life practice in France, unnecessary measures (potassium supplementation, peptic ulcer prevention, low-sodium diet) were frequently associated with long-term systemic glucocorticoid therapy, while consensual measures (osteoporosis prevention, vaccinations) were prescribed to less than half of patients.

    “unnecessary measures in most patients (potassium supplementation, prevention of”

    From ESPEN guideline on hospital nutrition (2021) · cites this paper as [168]

    Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 140

  1. Newton R Leigh R Giembycz MA Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases Pharmacol Ther 2010 125 286 327 10.1016/j.pharmthera.2009.11.003 19932713 · DOI
  2. Coutinho AE Chapman KE The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights Mol Cell Endocrinol 2011 335 2 13 10.1016/j.mce.2010.04.005 20398732 PMC3047790 · DOI · Paper page
  3. Croxtall JD van Hal PT Choudhury Q Gilroy DW Flower RJ Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells Br J Pharmacol 2002 135 511 519 10.1038/sj.bjp.0704474 11815387 PMC1573139 · DOI
  4. Stellato C Post-transcriptional and nongenomic effects of glucocorticoids Proc Am Thorac Soc 2004 1 255 263 10.1513/pats.200402-015MS 16113443 · DOI
  5. Deshmukh CT Minimizing side effects of systemic corticosteroids in children Indian J Dermatol Venereol Leprol 2007 73 218 221 10.4103/0378-6323.33633 17675727 · DOI
  6. Da Silva JA Jacobs JW Kirwan JR Boers M Saag KG Inês LB de Koning EJ Buttgereit F Cutolo M Capell H Rau R Bijlsma JW Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data Ann Rheum Dis 2006 65 285 293 10.1136/ard.2005.038638 16107513 PMC1798053 · DOI
  7. Yao W Cheng Z Busse C Pham A Nakamura MC Lane NE Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice Arthritis Rheum 2008 58 1674 1686 10.1002/art.23454 18512788 PMC3892702 · DOI · Paper page
  8. Manolagas SC Corticosteroids and fractures: a close encounter of the third cell kind J Bone Miner Res 2000 15 1001 1005 10.1359/jbmr.2000.15.6.1001 10841168 · DOI
  9. van Staa TP Leufkens HG Cooper C The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis Osteoporos Int 2002 13 777 787 10.1007/s001980200108 12378366 · DOI · Paper page
  10. Kanis JA Johansson H Oden A Johnell O de Laet C Melton LJ III Tenenhouse A Reeve J Silman AJ Pols HA Eisman JA McCloskey EV Mellstrom D A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 2004 19 893 899 10.1359/JBMR.040134 15125788 · DOI · Paper page
  11. Weinstein RS Glucocorticoid-induced osteonecrosis Endocrine 2012 41 183 190 10.1007/s12020-011-9580-0 22169965 PMC3712793 · DOI
  12. Kaste SC Karimova EJ Neel MD Osteonecrosis in children after therapy for malignancy Am J Roentgeno 2011 196 1011 1018 10.2214/AJR.10.6073 PMC4700933 21512065 · DOI
  13. Barr RD Sala A Osteonecrosis in children and adolescents with cancer Pediatr Blood Cancer 2008 50 2 Suppl 483 485 18064641
  14. Seamon J Keller T Saleh J Cui Q The pathogenesis of nontraumatic osteonecrosis Arthritis 2012 2012 601763 23243507 PMC3518945
  15. Zhao FC Li ZR Guo KJ Clinical analysis of osteonecrosis of the femoral head induced by steroids Orthop Surg 2012 4 28 34 10.1111/j.1757-7861.2011.00163.x 22290816 PMC6583143 · DOI
  16. Fauci AS Braunwald E Kasper DL Hauser SL Longo DL Jameson JL Loscalzo J Harrison’s Principles of Internal Medicine 2008 17 The McGraw-Hill Companies, Inc http://www.amazon.ca/books/dp/0071466339
  17. Livanou T Ferriman D James VH Recovery of hypothalamo-pituitary-adrenal function after corticosteroid therapy Lancet 1967 2 856 859 12387243
  18. Molimard M Girodet PO Pollet C Fourrier-Réglat A Daveluy A Haramburu F Fayon M Tabarin A Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation Drug Saf 2008 31 769 774 10.2165/00002018-200831090-00005 18707191 · DOI
  19. Habib GS Systemic effects of intra-articular corticosteroids Clin Rheumatol 2009 28 749 756 10.1007/s10067-009-1135-x 19252817 · DOI · Paper page
  20. Hengge UR Ruzicka T Schwartz RA Cork MJ Adverse effects of topical glucocorticosteroids J Am Acad Dermatol 2006 54 1 15 10.1016/j.jaad.2005.01.010 16384751 · DOI
  21. Ortega E Rodriguez C Strand LJ Segre E Effects of cloprednol and other corticosteroids on hypothalamic-pituitary-adrenal axis function J Int Med Res 1976 4 326 337 1028634
  22. Shulman DI Palmert MR Kemp SF Lawson Wilkins Drug and Therapeutics Committee Adrenal insufficiency: still a cause of morbidity and death in childhood Pediatrics 2007 119 e484 e494 10.1542/peds.2006-1612 17242136 · DOI · Paper page
  23. LaRochelle GE Jr LaRochelle AG Ratner RE Borenstein DG Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone Am J Med 1993 95 258 264 10.1016/0002-9343(93)90277-V 8368224 · DOI
  24. Einaudi S Bertorello N Masera N Farinasso L Barisone E Rizzari C Corrias A Villa A Riva F Saracco P Pastore G Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia Pediatr Blood Cancer 2008 50 537 541 10.1002/pbc.21339 17828747 · DOI
  25. Curtis JR Westfall AO Allison J Bijlsma JW Freeman A George V Kovac SH Spettell CM Saag KG Population-based assessment of adverse events associated with long-term glucocorticoid use Arthritis Rheum 2006 55 420 426 10.1002/art.21984 16739208 · DOI · Paper page
  26. Fardet L Cabane J Lebbé C Morel P Flahault A Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study J Am Acad Dermatol 2007 57 604 609 10.1016/j.jaad.2007.04.018 17582650 · DOI
  27. Schneiter P Tappy L Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans Am J Physiol 1998 275 E806 E813 9815000
  28. Gurwitz JH Bohn RL Glynn RJ Monane M Mogun H Avorn J Glucocorticoids and the risk for initiation of hypoglycemic therapy Arch Intern Med 1994 154 97 101 10.1001/archinte.1994.00420010131015 8267494 · DOI · Paper page
  29. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada Can J Diabetes 2013 37 Suppl 1 S1 S212 24070926
  30. American Diabetes Association Standards of medical care in diabetes — 2012 Diabetes Care 2012 35 Suppl 1 S11 S63 22187469 PMC3632172
  31. Black RL Oglesby RB von Sallman L Bunim JJ Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis JAMA 1960 174 166 171 10.1001/jama.1960.63030020005014 13801171 · DOI
  32. Urban RC Jr Cotlier E Corticosteroid-induced cataracts Surv Ophthalmol 1986 31 102 110 10.1016/0039-6257(86)90077-9 3541262 · DOI
  33. Armaly MF Effect of corticosteroids on intraocular pressure and fluid dynamics: The effect of dexamethasone in the normal eye Arch Ophthalmol 1963 70 482 491 10.1001/archopht.1963.00960050484010 14078870 · DOI
  34. Haimovici R Gragoudas ES Duker JS Sjaarda RN Eliott D Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids Ophthalmol 1997 104 1653 1660 10.1016/S0161-6420(97)30082-7 9331207 · DOI
  35. Schellenberg R Adachi JDR Bowie D Brown J Guenther L Kader T Trope GE Oral corticosteroids in asthma: a review of benefits and risks Can Respir J 2007 14 Suppl C 1C 7C
  36. Poetker DM Reh DD A comprehensive review of the adverse effects of systemic corticosteroids Otolaryngol Clin North Am 2010 43 753 768 10.1016/j.otc.2010.04.003 20599080 · DOI
  37. Conn HO Blitzer BL Nonassociation of adrenocorticosteroid therapy and peptic ulcer N Engl J Med 1976 294 434 479 173997
  38. Conn HO Poynard T Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy J Intern Med 1994 236 619 632 10.1111/j.1365-2796.1994.tb00855.x 7989897 · DOI
  39. Piper JM Ray WA Daugherty JR Griffin MR Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs Ann Intern Med 1991 114 735 740 10.7326/0003-4819-114-9-735 2012355 · DOI
  40. Messer J Reitman D Sacks HS Smith H Jr Chalmers TC Association of adrenocorticosteroid therapy and peptic-ulcer disease N Engl J Med 1983 309 21 24 10.1056/NEJM198307073090105 6343871 · DOI
  41. Sadr-Azodi O Mattsson F Bexlius TS Lindblad M Lagergren J Ljung R Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case–control study JAMA Intern Med 2013 173 444 449 10.1001/jamainternmed.2013.2737 23440105 · DOI
  42. Derk CT DeHoratius RJ Systemic lupus erythematosus and acute pancreatitis: a case series Clin Rheumatol 2004 23 147 151 10.1007/s10067-003-0793-3 15045630 · DOI
  43. Wei L MacDonald TM Walker BR Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease Ann Intern Med 2004 141 764 770 10.7326/0003-4819-141-10-200411160-00007 15545676 · DOI
  44. Souverein PC Berard A Van Staa TP Cooper C Egberts AC Leufkens HG Walker BR Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study Heart 2004 90 859 865 10.1136/hrt.2003.020180 15253953 PMC1768386 · DOI
  45. van der Hooft CS Heeringa J Brusselle GG Hofman A Witteman JC Kingma JH Sturkenboom MC Stricker BH Corticosteroids and the risk of atrial fibrillation Arch Intern Med 2006 166 1016 1020 10.1001/archinte.166.9.1016 16682576 · DOI
  46. Christiansen CF Christensen S Mehnert F Cummings SR Chapurlat RD Sørensen HT Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case–control study Arch Intern Med 2009 169 1677 1683 10.1001/archinternmed.2009.297 19822824 · DOI
  47. White KP Driscoll MS Rothe MJ Grant-Kels JM Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol 1994 30 768 773 10.1016/S0190-9622(08)81508-3 8176017 · DOI
  48. Moghadam-Kia S Werth VP Prevention and treatment of systemic glucocorticoid side effects Int J Dermatol 2010 49 239 248 10.1111/j.1365-4632.2009.04322.x 20465658 PMC2872100 · DOI
  49. Leong KH Koh ET Feng PH Boey ML Lipid profiles in patients with systemic lupus erythematosus J Rheumatol 1994 21 1264 1267 7966068
  50. Petri M Spence D Bone LR Hochberg MC Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices Medicine (Baltimore) 1992 71 291 302 1522805
  51. Svenson KL Lithell H Hällgren R Vessby B Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment Arch Intern Med 1987 147 1917 1920 10.1001/archinte.1987.00370110045006 3675092 · DOI
  52. Choi HK Seeger JD Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey Arthritis Rheum 2005 53 528 535 10.1002/art.21329 16082633 · DOI
  53. Bowyer SL LaMothe MP Hollister JR Steroid myopathy: incidence and detection in a population with asthma J Allergy Clin Immunol 1985 76 234 242 10.1016/0091-6749(85)90708-0 4019954 · DOI
  54. LaPier TK Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention J Cardiopulm Rehabil 1997 17 76 84 10.1097/00008483-199703000-00002 9101384 · DOI
  55. Latronico N Shehu I Seghelini E Neuromuscular sequelae of critical illness Curr Opin Crit Care 2005 11 381 390 10.1097/01.ccx.0000168530.30702.3e 16015120 · DOI
  56. Wolkowitz OM Burke H Epel ES Reus VI Glucocorticoids. Mood, memory, and mechanisms Ann N Y Acad Sci 2009 1179 19 40 10.1111/j.1749-6632.2009.04980.x 19906230 · DOI
  57. Warrington TP Bostwick JM Psychiatric adverse effects of corticosteroids Mayo Clin Proc 2006 81 1361 1367 10.4065/81.10.1361 17036562 · DOI
  58. Minden SL Orav J Schildkraut JJ Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis Neurology 1988 38 1631 1634 10.1212/WNL.38.10.1631 2843795 · DOI
  59. Bolanos SH Khan DA Hanczyc M Bauer MS Dhanani N Brown ES Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales Ann Allergy Asthma Immunol 2004 92 500 505 10.1016/S1081-1206(10)61756-5 15191017 · DOI
  60. Swinburn CR Wakefield JM Newman SP Jones PW Evidence of prednisolone induced mood change (‘steroid euphoria’) in patients with chronic obstructive airways disease Br J Clin Pharmacol 1988 26 709 713 10.1111/j.1365-2125.1988.tb05309.x 3242575 PMC1386585 · DOI
  61. Turner R Elson E Sleep disorders. Steroids cause sleep disturbance BMJ 1993 306 1477 1478 8518660 PMC1677864
  62. Brown ES Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy Ann N Y Acad Sci 2009 1179 41 55 10.1111/j.1749-6632.2009.04981.x 19906231 · DOI
  63. Keenan PA Jacobson MW Soleymani RM Mayes MD Stress ME Yaldoo DT The effect on memory of chronic prednisone treatment in patients with systemic disease Neurology 1996 47 1396 1402 10.1212/WNL.47.6.1396 8960717 · DOI
  64. Kershner P Wang-Cheng R Psychiatric side effects of steroid therapy Psychosomatics 1989 30 135 139 10.1016/S0033-3182(89)72293-3 2652177 · DOI
  65. Chau SY Mok CC Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus Neurology 2003 61 104 107 10.1212/WNL.61.1.104 12847167 · DOI
  66. Goggans FC Weisberg LJ Koran LM Lithium prophylaxis of prednisone psychosis: a case report J Clin Psychiatry 1983 44 111 112 6403514
  67. Stuck AE Minder CE Frey FJ Risk of infectious complications in patients taking glucocorticosteroids Rev Infect Dis 1989 11 954 963 10.1093/clinids/11.6.954 2690289 · DOI
  68. Saag KG Short-term and long-term safety of glucocorticoids in rheumatoid arthritis Bull NYU Hosp Jt Dis 2012 70 Suppl 1 21 25 23259654
  69. Grijalva CG Chen L Delzell E Baddley JW Beukelman T Winthrop KL Griffin MR Herrinton LJ Liu L Ouellet-Hellstrom R Patkar NM Solomon DH Lewis JD Xie F Saag KG Curtis JR Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases JAMA 2011 306 2331 2339 10.1001/jama.2011.1692 22056398 PMC3428224 · DOI
  70. Allen DB Mullen M Mullen B A meta-analysis of the effect of oral and inhaled corticosteroids on growth J Allergy Clin Immunol 1994 93 967 976 10.1016/S0091-6749(94)70043-5 8006318 · DOI
  71. Allen DB Growth suppression by glucocorticoid therapy Endocrinol Metab Clin North Am 1996 25 699 717 10.1016/S0889-8529(05)70348-0 8879994 · DOI
  72. Lettgen B Jeken C Reiners C Influence of steroid medication on bone mineral density in children with nephrotic syndrome Pediatr Nephrol 1994 8 667 670 10.1007/BF00869084 7696102 · DOI
  73. Falcini F Taccetti G Trapani S Tafi L Volpi M Growth retardation in juvenile chronic arthritis patients treated with steroids Clin Exp Rheumatol 1991 9 37 40 1711944
  74. Markowitz J Grancher K Rosa J Aiges H Daum F Growth failure in pediatric inflammatory bowel disease J Pediatr Gastroenterol Nutr 1993 16 373 380 10.1097/00005176-199305000-00005 8315544 · DOI
  75. Lai HC FitzSimmons SC Allen DB Kosorok MR Rosenstein BJ Campbell PW Farrell PM Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis N Engl J Med 2000 342 851 859 10.1056/NEJM200003233421204 10727589 · DOI
  76. Miller W Achermann J Frankland AW Sperling M The adrenal cortex and its disorders Pediatric Endocrinology 2008 3 Philadelphia: Saunders 444 511
  77. Rix M Birkebaek NH Rosthoj S Clausen N Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: a prospective observational study using the low-dose adrenocorticotropin test J Pediatr 2005 147 645 650 10.1016/j.jpeds.2005.06.006 16291357 · DOI
  78. Gordijn MS Gemke RJ van Dalen EC Rotteveel J Kaspers GJ Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia Cochrane Database Syst Rev 2012 5 CD008727 22592733
  79. Plager JE Cushman P Jr Suppression of the pituitary-ACTH response in man by administration of ACTH or cortisol J Clin Endocrinol Metab 1962 22 147 154 10.1210/jcem-22-2-147 14487062 · DOI
  80. Axelrod L Glucocorticoid therapy Medicine (Baltimore) 1976 55 39 65 10.1097/00005792-197601000-00003 173974 · DOI
  81. Amed S Dean H Sellers EA Panagiotopoulos C Shah BR Booth GL Laubscher TA Dannenbaum D Hadjiyannakis S Hamilton JK Risk factors for medication-induced diabetes and type 2 diabetes J Pediatr 2011 159 291 296 10.1016/j.jpeds.2011.01.017 21353243 · DOI
  82. Stratakis CA Cushing syndrome in pediatrics Endocrinol Metab Clin North Am 2012 41 793 803 10.1016/j.ecl.2012.08.002 23099271 PMC3594781 · DOI
  83. Semeao EJ Jawad AF Stouffer NO Zemel BS Piccoli DA Stallings VA Risk factors for low bone mineral density in children and young adults with Crohn’s disease J Pediatr 1999 135 593 600 10.1016/S0022-3476(99)70058-2 10547248 · DOI
  84. Boot AM Bouquet J Krenning EP de Muinck Keizer-Schrama SMPF Bone mineral density and nutritional status in children with chronic inflammatory bowel disease Gut 1998 42 188 194 10.1136/gut.42.2.188 9536942 PMC1726993 · DOI
  85. Kotaniemi A Savolainen A Kautiainen H Kröger H Estimation of central osteopenia in children with chronic polyarthritis treated with glucocorticoids Pediatrics 1993 91 1127 1130 8502514
  86. Bhudhikanok GS Wang M-C Marcus R Harkins A Moss RB Bachrach LK Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study J Pediatr 1998 133 18 27 10.1016/S0022-3476(98)70172-6 9672505 · DOI
  87. Conway SP Morton AM Oldroyd B Truscott JG White H Smith AH Haigh I Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors Thorax 2000 55 798 804 10.1136/thorax.55.9.798 10950902 PMC1745849 · DOI
  88. Bardare M Bianchi ML Furia M Gandolini GG Cohen E Montesano A Bone mineral metabolism in juvenile chronic arthritis: the influence of steroids Clin Exp Rheumatol 1991 9 Suppl 6 29 31 2060174
  89. Fantini F Beltrametti P Gallazzi M Gattinara M Gerloni V Murelli M Parrini M Evaluation by dual-photon absorptiometry of bone mineral loss in rheumatic children on long-term treatment with corticosteroids Clin Exp Rheumatol 1991 9 Suppl 6 21 28 2060173
  90. Perez MD Abrams SA Loddeke L Shypailo R Ellis KJ Effects of rheumatic disease and corticosteroid treatment on calcium metabolism and bone density in children assessed one year after diagnosis, using stable isotopes and dual energy X-ray absorptiometry J Rheumatol 2000 27 Suppl 58 38 43 10782855
  91. van Staa TP Cooper C Leufken HGM Bishop N Children and the risk of fractures caused by oral corticosteroids J Bone Miner Res 2003 18 913 918 10.1359/jbmr.2003.18.5.913 12733732 · DOI
  92. Halton J Gaboury I Grant R Alos N Cummings EA Matzinger M Shenouda N Lentle B Abish S Atkinson S Cairney E Dix D Israels S Stephure D Wilson B Hay J Moher D Rauch F Siminoski K Ward LM Canadian STOPP Consortium Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program J Bone Miner Res 2009 24 1326 1334 10.1359/jbmr.090202 19210218 PMC3890351 · DOI
  93. Huber AM Gaboury I Cabral DA Lang B Ni A Stephure D Taback S Dent P Ellsworth J LeBlanc C Saint-Cyr C Scuccimarri R Hay J Lentle B Matzinger M Shenouda N Moher D Rauch F Siminoski K Ward LM Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders Arthritis Care Res (Hoboken) 2010 62 516 526 10.1002/acr.20171 20391507 PMC3958950 · DOI
  94. Rodd C Lang B Ramsay T Alos N Huber AM Cabral DA Scuccimarri R Miettunen PM Roth J Atkinson SA Couch R Cummings EA Dent PB Ellsworth J Hay J Houghton K Jurencak R Larché M LeBlanc C Oen K Saint-Cyr C Stein R Stephure D Taback S Lentle B Matzinger M Shenouda N Moher D Rauch F Siminoski K Ward LM Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study Arthritis Care Res (Hoboken) 2012 64 122 131 10.1002/acr.20589 22213727 PMC4459856 · DOI
  95. Feber J Gaboury I Ni A Alos N Arora S Bell L Blydt-Hansen T Clarson C Filler G Hay J Hebert D Lentle B Matzinger M Midgley J Moher D Pinsk M Rauch F Rodd C Shenouda N Siminoski K Ward LM Canadian STOPP Consortium Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome Osteoporos Int 2012 23 751 760 10.1007/s00198-011-1621-2 21494860 PMC4000256 · DOI
  96. Papaioannou A Morin S Cheung AM Atkinson S Brown JP Feldman S Hanley DA Hodsman A Jamal SA Kaiser SM Kvern B Siminoski K Leslie WD Scientific Advisory Council of Osteoporosis Canada 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary CMAJ 2010 182 1864 1873 10.1503/cmaj.100771 20940232 PMC2988535 · DOI
  97. Rodrigues Pereira RM Carvalho JF Paula AP Zerbini C Domiciano DS Gonçalves H Danowski JS Marques Neto JF Mendonça LM Bezerra MC Terreri MT Imamura M Weingrill P Plapler PG Radominski S Tourinho T Szejnfeld VL Andrada NC Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis Rev Bras Reumatol 2012 52 580 593 10.1590/S0482-50042012000400009 22885424 · DOI
  98. Grossman JM Gordon R Ranganath VK Deal C Caplan L Chen W Curtis JR Furst DE McMahon M Patkar NM Volkmann E Saag KG American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Care Res (Hoboken) 2010 62 1515 1526 10.1002/acr.20295 20662044 · DOI
  99. Kanis JA Johansson H Oden A McCloskey EV Guidance for the adjustment of FRAX according to the dose of glucocorticoids Osteoporos Int 2011 22 809 816 10.1007/s00198-010-1524-7 21229233 · DOI
  100. Mushtaq T Ahmed SF The impact of corticosteroids on growth and bone health Arch Dis Child 2002 87 93 96 10.1136/adc.87.2.93 12138051 PMC1719206 · DOI · Paper page
  101. Carella MJ Srivastava LS Gossain VV Rovner DR Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy J Clin Endocrinol Metab 1993 76 1188 1191 10.1210/jc.76.5.1188 8388401 · DOI
  102. Erturk E Jaffe CA Barkan AL Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test J Clin Endocrinol Metab 1998 83 2350 2354 10.1210/jc.83.7.2350 9661607 · DOI
  103. Tordjman K Jaffe A Grazas N Apter C Stern N The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases J Clin Endocrinol Metab 1995 80 1301 1305 10.1210/jc.80.4.1301 7714104 · DOI
  104. Tordjman K Jaffe A Trostanetsky Y Greenman Y Limor R Stern N Low-dose (1 microgram) adrenocorticotropin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test Clin Endocrinol (Oxf) 2000 52 633 640 10.1046/j.1365-2265.2000.00984.x 10792344 · DOI
  105. Anderson TJ Grégoire J Hegele RA Couture P Mancini GB McPherson R Francis GA Poirier P Lau DC Grover S Genest J Jr Carpentier AC Dufour R Gupta M Ward R Leiter LA Lonn E Ng DS Pearson GJ Yates GM Stone JA Ur E 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 2013 29 151 167 10.1016/j.cjca.2012.11.032 23351925 · DOI
  106. Davidson J Wilkinson AH Dantal J Dotta F Haller H Hernández D Kasiske BL Kiberd B Krentz A Legendre C Marchetti P Markell M van der Woude FJ Wheeler DC International Expert Panel New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003 Transplantation 2003 7 SS3 SS24 12775942
  107. Humbert M Beasley R Ayres J Slavin R Hébert J Bousquet J Beeh KM Ramos S Canonica GW Hedgecock S Fox H Blogg M Surrey K Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 2005 60 309 316 10.1111/j.1398-9995.2004.00772.x 15679715 · DOI
  108. Lougheed MD Lemiere C Ducharme FM Licskai C Dell SD Rowe BH Fitzgerald M Leigh R Watson W Boulet LP Canadian Thoracic Society Asthma Clinical Assembly Canadian Thoracic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults Can Respir J 2012 19 127 164 22536582 PMC3373283
  109. Devogelaer JP Goemaere S Boonen S Body JJ Kaufman JM Reginster JY Rozenberg S Boutsen Y Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club Osteoporos Int 2006 17 8 19 10.1007/s00198-005-2032-z 16217586 · DOI
  110. Nawata H Soen S Takayanagi R Tanaka I Takaoka K Fukunaga M Matsumoto T Suzuki Y Tanaka H Fujiwara S Miki T Sagawa A Nishizawa Y Seino Y Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004) J Bone Miner Metab 2005 23 105 109 10.1007/s00774-004-0596-x 15750687 · DOI
  111. Homik J Cranney A Shea B Tugwell P Wells G Adachi R Suarez-Almazor M Bisphosphonates for steroid induced osteoporosis Cochrane Database Syst Rev 2000 2 CD001347 10796432
  112. Adachi JD Bensen WG Brown J Hanley D Hodsman A Josse R Kendler DL Lentle B Olszynski W Ste-Marie LG Tenenhouse A Chines AA Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis N Engl J Med 1997 337 382 387 10.1056/NEJM199708073370603 9241127 · DOI
  113. Saag KG Emkey R Schnitzer TJ Brown JP Hawkins F Goemaere S Thamsborg G Liberman UA Delmas PD Malice MP Czachur M Daifotis AG Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis N Engl J Med 1998 339 292 299 10.1056/NEJM199807303390502 9682041 · DOI · Paper page
  114. Cohen S Levy RM Keller M Boling E Emkey RD Greenwald M Zizic TM Wallach S Sewell KL Lukert BP Axelrod DW Chines AA Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 1999 42 2309 2318 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K 10555025 · DOI
  115. Wallach S Cohen S Reid DM Hughes RA Hosking DJ Laan RF Doherty SM Maricic M Rosen C Brown J Barton I Chines AA Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy Calcif Tissue Int 2000 67 277 285 10.1007/s002230001146 11000340 · DOI
  116. Reid DM Devogelaer JP Saag K Roux C Lau CS Reginster JY Papanastasiou P Ferreira A Hartl F Fashola T Mesenbrink P Sambrook PN HORIZON investigators Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 2009 373 1253 1263 10.1016/S0140-6736(09)60250-6 19362675 · DOI · Paper page
  117. Roux C Reid DM Devogelaer JP Saag K Lau CS Reginster JY Papanastasiou P Bucci-Rechtweg C Su G Sambrook PN Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis Osteoporos Int 2012 23 1083 1090 10.1007/s00198-011-1800-1 21975559 · DOI
  118. Saag KG Zanchetta JR Devogelaer JP Adler RA Eastell R See K Krege JH Krohn K Warner MR Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six–month results of a randomized, double-blind, controlled trial Arthritis Rheum 2009 60 3346 3355 10.1002/art.24879 19877063 · DOI · Paper page
  119. Karras D Stoykov I Lems WF Langdahl BL Ljunggren Ö Barrett A Walsh JB Fahrleitner-Pammer A Rajzbaum G Jakob F Marin F Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study J Rheumatol 2012 39 600 609 10.3899/jrheum.110947 22247365 · DOI
  120. Cranney A Welch V Adachi JD Homik J Shea B Suarez-Almazor ME Tugwell P Wells G Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis Cochrane Database Syst Rev 2000 2 CD001983 10796457 PMC8409281
  121. Ettinger B Black DM Mitlak BH Knickerbocker RK Nickelsen T Genant HK Christiansen C Delmas PD Zanchetta JR Stakkestad J Glüer CC Krueger K Cohen FJ Eckert S Ensrud KE Avioli LV Lips P Cummings SR Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 1999 282 637 645 10.1001/jama.282.7.637 10517716 · DOI · Paper page
  122. Hofbauer LC Zeitz U Schoppet M Skalicky M Schüler C Stolina M Kostenuik PJ Erben RG Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL Arthritis Rheum 2009 60 1427 1437 10.1002/art.24445 19404943 · DOI
  123. Dore RK Cohen SB Lane NE Palmer W Shergy W Zhou L Wang H Tsuji W Newmark R Denosumab RA Study Group Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates Ann Rheum Dis 2010 69 872 875 10.1136/ard.2009.112920 19734132 PMC6909937 · DOI
  124. Papapoulos S Chapurlat R Libanati C Brandi ML Brown JP Czerwiński E Krieg MA Man Z Mellström D Radominski SC Reginster JY Resch H Román Ivorra JA Roux C Vittinghoff E Austin M Daizadeh N Bradley MN Grauer A Cummings SR Bone HG Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension J Bone Miner Res 2012 27 694 701 10.1002/jbmr.1479 22113951 PMC3415620 · DOI
  125. Homik J Suarez-Almazor ME Shea B Cranney A Wells G Tugwell P Calcium and vitamin D for corticosteroid-induced osteoporosis Cochrane Database Syst Rev 2000 2 CD000952 10796394 PMC7046131
  126. Institute of Medicine Dietary reference intakes for calcium and vitamin D 2011 Washington, DC: The National Academies Press 21796828
  127. Holick MF Binkley NC Bischoff-Ferrari HA Gordon CM Hanley DA Heaney RP Murad MH Weaver CM Endocrine Society Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 2011 96 1911 1930 10.1210/jc.2011-0385 21646368 · DOI
  128. Ward L Tricco AC Phuong P Cranney A Barrowman N Gaboury I Rauch F Tugwell P Moher D Bisphosphonate therapy for children and adolescents with secondary osteoporosis Cochrane Database Syst Rev 2007 4 CD005324 17943849 PMC8884163
  129. Bachrach LK Ward LM Clinical review 1: Bisphosphonate use in childhood osteoporosis J Clin Endocrinol Metab 2009 94 400 409 10.1210/jc.2008-1531 19033370 · DOI
  130. Sbrocchi AM Rauch F Jacob P McCormick A McMillan HJ Matzinger MA Ward LM The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy Osteoporos Int 2012 23 2703 2711 10.1007/s00198-012-1911-3 22297733 · DOI
  131. Sbrocchi AM Forget S Laforte D Azouz EM Rodd C Zoledronic acid for the treatment of osteopenia in pediatric Crohn’s disease Pediatr Int 2010 52 754 761 10.1111/j.1442-200X.2010.03174.x 20524999 · DOI
  132. Lai KA Shen WJ Yang CY Shao CJ Hsu JT Lin RM The use of alendronate to prevent early collapse of the femoral head in patients with non-traumatic osteonecrosis. A randomized clinical study J Bone Joint Surg Am 2005 87 2155 2159 10.2106/JBJS.D.02959 16203877 · DOI
  133. Agarwala S Shah SB Ten year followup of avascular necrosis of femoral head treated with alendronate for 3 years J Arthroplasty 2011 26 1128 1134 10.1016/j.arth.2010.11.010 21256699 · DOI
  134. Chen CH Chang JK Lai KA Hou SM Chang CH Wang GJ Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study Arthritis Rheum 2012 64 1572 1578 10.1002/art.33498 22127729 · DOI
  135. Kotecha RS Powers N Lee SJ Murray KJ Carter T Cole C Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL) Pediatr Blood Cancer 2010 54 934 940 20127847
  136. Leblicq C Laverdière C Décarie JC Delisle JF Isler MH Moghrabi A Chabot G Alos N Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia Pediatr Blood Cancer 2013 60 741 747 10.1002/pbc.24313 23002054 · DOI
  137. Coursin DB Wood KE Corticosteroid supplementation for adrenal insufficiency JAMA 2002 287 236 240 10.1001/jama.287.2.236 11779267 · DOI
  138. Salem M Tainsh RE Jr Bromberg J Loriaux DL Chernow B Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem Ann Surg 1994 219 416 425 10.1097/00000658-199404000-00013 8161268 PMC1243159 · DOI · Paper page
  139. Ahmed SF Tucker P Mushtaq T Wallace AM Williams DM Hughes IA Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone Clin Endocrinol (Oxf) 2002 57 185 191 10.1046/j.1365-2265.2002.01580.x 12153596 · DOI
  140. Allen DB Julius JR Breen TJ Treatment of glucocorticoid-induced growth suppression with growth hormone. On behalf of the National Cooperative Growth Study J Clin Endocrinol Metab 1998 83 2824 2829 10.1210/jc.83.8.2824 9709954 · DOI · Paper page

Cited by

Sorted by citations

Authors
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H.
Affiliations
  • Western University (CA)
  • University of Ottawa (CA)
  • Montreal Children's Hospital (CA)
  • University Health Network (CA)
  • University of Calgary (CA)
  • Université Laval (CA)
  • Jewish General Hospital (CA)
Corresponding author
Kim, Harold
ORCID
Venue
Allergy, Asthma & Clinical Immunology
Publisher
Springer Science and Business Media LLC
Published
2013-08-15
Volume
9
Issue
1
Pages
30-30
ISSN
  • 1710-1484 (ISSN-L)
  • 1710-1492
DOI
10.1186/1710-1492-9-30
PMC
PMC3765115
OpenAlex
W2141351444
Cited by
1,268
References
12
Citations by year
2026: 93 · 2025: 126 · 2024: 143 · 2023: 152 · 2022: 162 · 2021: 144 · 2020: 122 · 2019: 97 · 2018: 83 · 2017: 65 · 2016: 42 · 2015: 27 · 2014: 8 · 2013: 1
FWCI
20.49
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Allergy Asthma and Clinical Immunology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • uO Research (University of Ottawa) (submittedVersion, public-domain)
Funders
University of Ottawa
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
systemic corticosteroids, adverse drug reactions, osteoporosis, adrenal suppression, hyperglycemia, dyslipidemia, cardiovascular disease, Cushing's syndrome, psychiatric disturbances, immunosuppression, monitoring, prevention, long-term corticosteroid therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review